DGAP-News: Cytos Biotechnology Ltd announces terms for capital increase
05.11.2013 – 07:06
EQS Group-News: Cytos Biotechnology AG / Key word(s): Capital Increase Cytos Biotechnology Ltd announces terms for capital increase 05.11.2013 / 07:00 --------------------------------------------------------------------- This media release and the information contained herein is not being issued in and may not be distributed directly or indirectly in certain countries, including the United States, Canada, Australia, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction where it might be unlawful to do so. This media release does not constitute an offer for the sale of securities. Cytos Biotechnology announces terms for capital increase New registered shares are issued for CHF 3.00; 32 existing shares entitle to subscribe for 9 new shares Schlieren (Zurich), Switzerland, November 5, 2013 - Cytos Biotechnology AG (SIX:CYTN) ('Cytos') has announced the terms for a capital increase in the form of a rights offering as follows: Shares are issued for CHF 3.00 and 32 existing shares entitle to subscribe for 9 new registered shares. Cytos shareholders will receive additional information regarding the exercise of the subscription rights via their bank or broker in the coming days. Shareholders interested to subscribe shares beyond their subscription rights must contact the Company's CFO Harry Welten (harry.welten@cytos.com; Telephone: +41 (0)44 733 46 46) until November 13, 2013. As previously announced, the group of institutional and strategic shareholders that invested in the Company in 2012, namely Abingworth, venBio, Aisling and Amgen, will increase their investment by CHF 9 million as part of the rights offering. The Company's board of directors intends to make available to new investors any shares that are not subscribed by the current shareholders in the rights offering. The following timetable is expected for the capital increase: November 5, Last trading day in existing shares incl. rights 2013 November 6, First trading day in existing shares ex-rights, start of 2013 rights exercise period November 15, End of rights exercise period (12.00 CET) 2013 November 20, Listing of new shares from rights issue 2013 November 21, Payment and settlement 2013 The offering and listing prospectus dated November 5, 2013 is solely relevant for the capital increase. This prospectus is available free of charge from the Company (Telephone: +41 (0)44 733 47 47, facsimile: +41 (0)44 733 47 40, e-mail: info@cytos.com). If fully subscribed, the share placement is expected to result in the issuance of up to 6,303,215 new registered Cytos-shares with a nominal value of CHF 0.10 each. For further information, please contact: Cytos Biotechnology Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 e-mail: harry.welten@cytos.com About Cytos Biotechnology Ltd Cytos is a public biopharmaceutical company focused on the development of targeted immuno-therapies. The Company's lead product candidate CYT003 is a novel, first-in-class, immune modulator in Phase 2 clinical development as a potential new treatment for asthma.CYT003 has a novel mechanism of action that inhibits the immune response that causes asthma, and may therefore be beneficial for the control of asthma. In a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and lung function in patients with persistent allergic asthma, despite withdrawal of standard therapy with inhaled corticosteroids. CYT003 has been shown to have a good safety and tolerability profile in more than 450 individuals receiving the active agent so far.Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology (ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN. www.cytos.com Disclaimer This document does neither constitute an offer to buy or to subscribe for securities of Cytos Biotechnology Ltd nor a prospectus within the meaning of applicable Swiss law. Investors should make their decision to buy or to subscribe to securities of Cytos Biotechnology Ltd solely based on the official offering and listing prospectus which will be published by Cytos Biotechnology Ltd. Investors are furthermore advised to consult their bank or financial adviser before making any investment decision. This document does not constitute a prospectus pursuant to article 652a or 1156 of the Swiss Code of Obligations or article 27 et seq. of the listing rules of the SIX Swiss Exchange Ltd. A decision to invest in securities of Cytos Biotechnology Ltd should be based exclusively on the offering and listing prospectus published by Cytos Biotechnology Ltd for such purpose. The securities described herein are offered publicly in Switzerland only. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. This document is not being issued in the United States of America, Canada, Australia, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction where it might be unlawful to do so and should not be distributed or otherwise transmitted into the United States, or any other of the aforementioned jurisdictions, or to U.S. persons (as defined in the U.S. Securities Act of 1933, as amended) or publications with a general circulation in the United States or any other of the aforementioned jurisdictions. This document does not constitute an offer or invitation to subscribe for or to purchase any securities in the United States of America or any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933. Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words 'will' or 'expect' or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, including that CYT003 may not demonstrate safety or efficacy in clinical trials, that there may be delays in development or that CYT003 may not receive marketing approval, and that the Company relies on outside financing to meet capital requirements, which may not be available under acceptable terms or at all. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments. End of Corporate News +++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=UCYURUVIIE Document title: Cytos_Press_E_131105 --------------------------------------------------------------------- 05.11.2013 This Corporate News was distributed by EQS Schweiz AG. www.eqs.com - news archive: http://switzerland.eqs.com/de/News The issuer is responsible for the contents of the release. --------------------------------------------------------------------- Language: English Company: Cytos Biotechnology AG Wagistr. 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@cytos.com Internet: www.cytos.com ISIN: CH0011025217, CH0029060735 Valor: - Listed: Freiverkehr in Berlin, München, Stuttgart; Frankfurt in Open Market ; SIX End of News EQS Group News-Service --------------------------------------------------------------------- 237764 05.11.2013